Los pacientes siguen un calendario sencillo de titulación de dosis de 4 semanas, diseñado para minimizar los posibles efectos secundarios gastrointestinales1

1.- Saxenda®, Información para Prescribir, 16.08.2018 (183300415U0042).

2.- Pi-Sunyer X, Astrup A, Fujioka K, et al. for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22.

3.- Pi-Sunyer X, Astrup A, Fujioka K, et al. for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. Supplementary Information. N Engl J Med. 2015;373(1): 11-22.

4.- Wadden TA, Hollander P, Klein S, et al. on behalf of NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451. [Erratum: Int J Obes ( Lond). 2013;37:1514. doi:10.1038/ijo.2013.1 48.]

5.- Saxenda [prescribing information]. Bagsvaerd, Denmark: Novo Nordisk A/S; August 2018.

6.- Data on file. Tips that may help you manage some common side effects; 2017. Bagsvcerd, Denmark: Novo Nordisk A/5.

7.- Fujioka K, O’Neil PM, Davies M, et al. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity (Silver Spring). 2016;24(11):2278-2288.